Navigation Links
Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
Date:4/29/2011

SAN DIEGO, April 29, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences:

  • JMP Securities Tenth Annual Research Conference on Tuesday, May 10, 2011 at 2:30 p.m. Pacific Time at the Ritz-Carlton in San Francisco.
  • Bank of America Merrill Lynch 2011 Health Care Conference on Thursday, May 12, 2011 at 9:50 a.m. Pacific Time at Encore at Wynn Las Vegas.
  • UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24, 2011 at 12:00 p.m. British Summer Time at the UBS offices in London.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of Optimer's NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.  

Contacts

Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
2. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
3. Trading Halted Today in Optimer Pharmaceuticals Stock
4. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
5. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
6. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
7. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
9. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
10. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
11. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... , Feb. 12, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased to ... Account Management and Payor Strategies effective Jan. 23, 2016. ... ... ... Diplomat Specialty Pharmacy ...
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... The producers of Enterprises TV are pleased to present ... world of instantaneous consumption proves very convenient for businesses. With new technologies constantly becoming ... which pollutes our air, water, and soil. It can also threaten the lives of ...
(Date:2/13/2016)... ... 13, 2016 , ... DDi , a Makro company, ... for its expertise in eClinical Solutions. DDi has built its solution competency with ... of global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker ... Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and ... hydrated before the big event. The invitation-only gifting suite, held this year at the ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Fisher House ... Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy ... at the VA Southern Nevada Healthcare System. This will be the first Fisher ...
Breaking Medicine News(10 mins):